Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
Source: The Asco Post, September 2022
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival outcomes in previously untreated patients with BRAF V600–mutant metastatic melanoma.
As stated by the investigators, “Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAF V600–mutant metastatic melanoma.”
Study Details
In the open-label noncomparative trial, 209 patients from sites in nine countries were randomly assigned 1:1:1 between November 2016 to May 2019 to receive:
- Encorafenib at 450 mg once daily plus binimetinib at 45 mg twice daily until disease progression, followed by ipilimumab at 3 mg/kg plus nivolumab at 1 mg/kg once every 3 weeks for four cycles, and then nivolumab at 3 mg/kg every 2 weeks (n = 69)
- Ipilimumab/nivolumab until disease progression followed by encorafenib/binimetinib (n = 71)
- A “sandwich” approach consisting of encorafenib/binimetinib for 8 weeks, followed by ipilimumab/nivolumab until disease progression, and then encorafenib/binimetinib (n = 69).